3-methoxyphencyclidine (also known as 3-meo-pcp) is a lesser-known novel dissociative substance of the arylcyclohexylamine class. 3-meo-pcp is a derivative of phencyclidine (pcp) and is chemically related to substances like methoxetamine and 3-meo-pce. it produces its effects by blocking nmda receptors in the brain.
3-meo-pcp was first synthesized in 1979 in an investigation of phencyclidine (pcp) derivatives. however, its activity in humans was not described until 1999 when a chemist using the pseudonym john q. beagle reported qualitative similarities to pcp along with comparable potency. in 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the research chemicals market.
like other arylcyclohexlyamines, 3-meo-pcp induces a state referred to as “dissociative anesthesia“, although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. it is commonly taken orally and nasally, although it may also be smoked and injected. it has been noted for its subtle come up and tendency to produce delusions of sobriety, which can lead to compulsive redosing.
very little data exists for the pharmacology, metabolism, and toxicity of 3-meo-pcp. due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use harm reduction practices if using this substance.
3-methoxyphencyclidine, or 3-meo-pcp, is a synthetic dissociative of the arylcyclohexylamine class. 3-meo-pcp contains cyclohexane, a six-member saturated ring, bonded to two additional rings at r1. one of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. the other ring is an aromatic phenyl ring, substituted at r3 with a methoxy group.
3-meo-pcp acts as an nmda receptor antagonist. a specific subtype of glutamate receptor, nmda (n-methyl-d-aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.
dissociatives inhibit the normal functioning nmda receptors by binding to and blocking them. this disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a “k-hole”.
3-meo-pcp has a ki of 20 nm for the nmda receptor, 216 nm for the serotonin transporter (sert), 42 nm for the sigma-1 receptor and 2960 nm with h1 receptor it binds to the nmda receptor with higher affinity than pcp and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-meo-pcp and 4-meo-pcp.
although 3-meo-pcp was once claimed to possess opioid or dopaminergic activity, this supposition is contradicted by data showing 3-meo-pcp to be a potent and selective ligand for the nmda receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter. 3-meo-pcp was preceded by the less potent dissociative 4-meo-pcp and first became available as a research chemical in 2011.